Researchers from Western Oklahoma Blood and Marrow Transplant Program have reported that a single 6 mg injection of Neulasta™ (pegfilgrastim) was as effective as multiple days of granulocyte-colony stimulating factor (filgrastim, Neupogen®) for the mobilization of peripheral blood stem cells in patients undergoing autologous transplantation. The results of this study were presented at the Tandem BMT Meetings in Orlando Florida February 13-17, 2004. This was a joint meeting between the International Bone Marrow Transplant Registry and the American Society for Blood and Marrow Transplantation (IBMTR/ASBMT).
Pegylation is a technique that allows for the slow delivery of biologic agents, cutting down the need for daily dosing. It has been used successfully to develop Aranesp®, which is a long-acting form of recombinant human erythropoietin. Aranesp® can be given at weekly or longer intervals. The same technology has been used to develop Neulasta®, a long-acting form of Neupogen®).
In the Western Oklahoma study, 13 patients with malignancies were given a single 6 mg dose of Neulasta® after mobilizing chemotherapy followed by the collection of peripheral blood stem cells. The researchers concluded that a single 6 mg injection of Neulasta® after chemotherapy could be substituted for daily Neupogen®.
Reference: Pegfilgrastim (Neulasta™) Following Chemotherapy Leads to Successful Mobilization of Hematopoetic Progenitor Cells Among Transplant Patients with Various Malignancies.
Two Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
Research suggests some patients with CML can safely discontinue TKI therapy - NCCN guidelines published.
Biology of Blood and Marrow Transplantation 2004;10:14, supplement 1, Abstract #21.
Copyright © 2018 CancerConnect. All Rights Reserved.